Publication
Witkiewicz et al. Nat Commun 2015
Authors not recorded
2015PMID 25855536stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CBIOPORTAL-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- cancerPancreatic Adenocarcinomacbioportal_study1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25855536
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS G12D1 | ||||||||
| Vemurafenib | Malignant Pancreatic Neoplasm | Predictive | D | Supports Resistance | — | submitted | EID3959In an in vitro study, PLX-4032 cell lines expressing KRAS G12D mutation demonstrated resistance to vemurafenib treatment, compared to PDA_014 cell expressing BRAF V600E mutation (a known sensitizing m… (full text at CIViC) PMID 25855536 · Witkiewicz et al., 2015 · Open in CIViC | civic |